Peptide record

TPDB11911

β-Amyloid1-40 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Blood-Brain Barrier standard
40 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11911
β-Amyloid1-40
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Blood-Brain Barrier
Anti-infective peptides Cancer-related peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP Peptipedia Antifungipept CAFPdb AI4AVP DRAVP 2.0 BBPpredict
standard
No
A 40-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
Sequence
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C194H295N53O58S1
CPTW
GV
4329.86
5.21
6
6
18
-3
0.99
0.058
90.00
Mammalian: 1.1 hour Yeast: 3 min E.coli: >10 hour
1490
0.34
5
Residue Composition
number
3
A
1
R
1
N
3
D
0
C
3
E
1
Q
6
G
3
H
2
I
2
L
2
K
1
M
3
F
0
P
2
S
0
T
0
W
1
Y
6
V
Amino Acid Distribution
A: 3 R: 1 N: 1 D: 3 C: 0 E: 3 Q: 1 G: 6 H: 3 I: 2 L: 2 K: 2 M: 1 F: 3 P: 0 S: 2 T: 0 W: 0 Y: 1 V: 6
Chemical Descriptors
40 reviewed residue count
C194H295N53O58S1 sequence-only estimate (linear, free termini)
4329.86 sequence-only estimate (linear, free termini)
5.21 sequence-only estimate (linear, free termini)
-3 sequence-only estimate (linear, free termini)
0.99 sequence-only estimate (linear, free termini)
0.058 sequence-only estimate (linear, free termini)
Linear Activity
Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val Activity
CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)N Activity
Evidence Records 34 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.78 µg/mL

Target

Candida albicans ATCC 10231

Source & Reference

dbAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class.
active against C. albicans ATCC 10231 (MIC 0.78 ug/ml), E. coli ATCC 25922 (MIC 1.56 ug/ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumo
Evidence 2 Activity

Activity

MIC
Antibacterial
1.56 µg/mL

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP

Other

active against C. albicans ATCC 10231 (MIC 0.78 ug/ml), E. coli ATCC 25922 (MIC 1.56 ug/ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S.
Evidence 3 Activity

Activity

MIC
Antibacterial
50 µg/mL

Target

Staphylococcus epidermidis ATCC 12228

Source & Reference

dbAMP

Other

ive against C. albicans ATCC 10231 (MIC 0.78 ug/ml), E. coli ATCC 25922 (MIC 1.56 ug/ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monoc
Evidence 4 Activity

Activity

MIC
Antibacterial
25 µg/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

dbAMP

Other

ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. ag
Evidence 5 Activity

Activity

MIC
Antibacterial
25 µg/mL

Target

L. monocytogenes ATCC 19112

Source & Reference

dbAMP

Other

0 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. agalactiae ATCC 12386 (MIC 50 ug/ml), P-aerugi
Evidence 6 Activity

Activity

MIC
Antibacterial
50 µg/mL

Target

Enterococcus faecalis ATCC 29212

Source & Reference

dbAMP

Other

ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. agalactiae ATCC 12386 (MIC 50 ug/ml), P-aeruginosa ATCC 27853 (MIC>50 ug/ml), S-pyoge
Evidence 7 Activity

Activity

MIC
Antibacterial
50 µg/mL

Target

Streptococcus agalactiae ATCC 12386

Source & Reference

dbAMP

Other

g/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. agalactiae ATCC 12386 (MIC 50 ug/ml), P-aeruginosa ATCC 27853 (MIC>50 ug/ml), S-pyogenes ATCC 19615 (MIC>50 ug/ml), S. mitis A
Evidence 8 Activity

Activity

MIC
Antibacterial
50 µg/mL

Target

S. mitis ATCC 6249

Source & Reference

dbAMP

Other

50 ug/ml), P-aeruginosa ATCC 27853 (MIC>50 ug/ml), S-pyogenes ATCC 19615 (MIC>50 ug/ml), S. mitis ATCC 6249 (MIC 50 ug/ml), abd S-salivarius ATCC 13419 (MIC > 50 ug/ml). It also inhibits Herpes simplex virus 1 (H
Evidence 9 Activity

Activity

MIC
Antifungal
0.78 µg/mL

Target

Candida albicans ATCC 10231

Source & Reference

dbAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class.
active against C. albicans ATCC 10231 (MIC 0.78 ug/ml), E. coli ATCC 25922 (MIC 1.56 ug/ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumo
Evidence 10 Activity

Activity

MIC
Antifungal
1.56 µg/mL

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP CAFPdb Antifungipept

Other

active against C. albicans ATCC 10231 (MIC 0.78 ug/ml), E. coli ATCC 25922 (MIC 1.56 ug/ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S.
Evidence 11 Activity

Activity

MIC
Antifungal
50 µg/mL

Target

Staphylococcus epidermidis ATCC 12228

Source & Reference

dbAMP CAFPdb Antifungipept

Other

ive against C. albicans ATCC 10231 (MIC 0.78 ug/ml), E. coli ATCC 25922 (MIC 1.56 ug/ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monoc
Evidence 12 Activity

Activity

MIC
Antifungal
25 µg/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

dbAMP CAFPdb Antifungipept

Other

ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. ag
Evidence 13 Activity

Activity

MIC
Antifungal
25 µg/mL

Target

L. monocytogenes ATCC 19112

Source & Reference

dbAMP CAFPdb Antifungipept

Other

0 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. agalactiae ATCC 12386 (MIC 50 ug/ml), P-aerugi
Evidence 14 Activity

Activity

MIC
Antifungal
50 µg/mL

Target

Enterococcus faecalis ATCC 29212

Source & Reference

dbAMP CAFPdb Antifungipept

Other

ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. agalactiae ATCC 12386 (MIC 50 ug/ml), P-aeruginosa ATCC 27853 (MIC>50 ug/ml), S-pyoge
Evidence 15 Activity

Activity

MIC
Antifungal
50 µg/mL

Target

Streptococcus agalactiae ATCC 12386

Source & Reference

dbAMP CAFPdb Antifungipept

Other

g/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. agalactiae ATCC 12386 (MIC 50 ug/ml), P-aeruginosa ATCC 27853 (MIC>50 ug/ml), S-pyogenes ATCC 19615 (MIC>50 ug/ml), S. mitis A
Evidence 16 Activity

Activity

MIC
Antifungal
50 µg/mL

Target

S. mitis ATCC 6249

Source & Reference

dbAMP CAFPdb Antifungipept

Other

50 ug/ml), P-aeruginosa ATCC 27853 (MIC>50 ug/ml), S-pyogenes ATCC 19615 (MIC>50 ug/ml), S. mitis ATCC 6249 (MIC 50 ug/ml), abd S-salivarius ATCC 13419 (MIC > 50 ug/ml). It also inhibits Herpes simplex virus 1 (H
Evidence 17 Activity

Activity

MIC
Antiparasitic
0.78 µg/mL

Target

Candida albicans ATCC 10231

Source & Reference

NA

Other

active against C. albicans ATCC 10231 (MIC 0.78 ug/ml), E. coli ATCC 25922 (MIC 1.56 ug/ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumo
Evidence 18 Activity

Activity

MIC
Antiparasitic
1.56 µg/mL

Target

Escherichia coli ATCC 25922

Source & Reference

NA

Other

active against C. albicans ATCC 10231 (MIC 0.78 ug/ml), E. coli ATCC 25922 (MIC 1.56 ug/ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S.
Evidence 19 Activity

Activity

MIC
Antiparasitic
50 µg/mL

Target

Staphylococcus epidermidis ATCC 12228

Source & Reference

NA

Other

ive against C. albicans ATCC 10231 (MIC 0.78 ug/ml), E. coli ATCC 25922 (MIC 1.56 ug/ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monoc
Evidence 20 Activity

Activity

MIC
Antiparasitic
25 µg/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

NA

Other

ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. ag
Evidence 21 Activity

Activity

MIC
Antiparasitic
25 µg/mL

Target

L. monocytogenes ATCC 19112

Source & Reference

NA

Other

0 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. agalactiae ATCC 12386 (MIC 50 ug/ml), P-aerugi
Evidence 22 Activity

Activity

MIC
Antiparasitic
50 µg/mL

Target

Enterococcus faecalis ATCC 29212

Source & Reference

NA

Other

ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. agalactiae ATCC 12386 (MIC 50 ug/ml), P-aeruginosa ATCC 27853 (MIC>50 ug/ml), S-pyoge
Evidence 23 Activity

Activity

MIC
Antiparasitic
50 µg/mL

Target

Streptococcus agalactiae ATCC 12386

Source & Reference

NA

Other

g/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. agalactiae ATCC 12386 (MIC 50 ug/ml), P-aeruginosa ATCC 27853 (MIC>50 ug/ml), S-pyogenes ATCC 19615 (MIC>50 ug/ml), S. mitis A
Evidence 24 Activity

Activity

MIC
Antiparasitic
50 µg/mL

Target

S. mitis ATCC 6249

Source & Reference

NA

Other

50 ug/ml), P-aeruginosa ATCC 27853 (MIC>50 ug/ml), S-pyogenes ATCC 19615 (MIC>50 ug/ml), S. mitis ATCC 6249 (MIC 50 ug/ml), abd S-salivarius ATCC 13419 (MIC > 50 ug/ml). It also inhibits Herpes simplex virus 1 (H
Evidence 25 Activity

Activity

MIC
Antiviral
0.78 µg/mL

Target

Candida albicans ATCC 10231

Source & Reference

DRAVP 2.0

Other

active against C. albicans ATCC 10231 (MIC 0.78 ug/ml), E. coli ATCC 25922 (MIC 1.56 ug/ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumo
Evidence 26 Activity

Activity

MIC
Antiviral
1.56 µg/mL

Target

Escherichia coli ATCC 25922

Source & Reference

DRAVP 2.0

Other

active against C. albicans ATCC 10231 (MIC 0.78 ug/ml), E. coli ATCC 25922 (MIC 1.56 ug/ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S.
Evidence 27 Activity

Activity

MIC
Antiviral
50 µg/mL

Target

Staphylococcus epidermidis ATCC 12228

Source & Reference

DRAVP 2.0

Other

ive against C. albicans ATCC 10231 (MIC 0.78 ug/ml), E. coli ATCC 25922 (MIC 1.56 ug/ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monoc
Evidence 28 Activity

Activity

MIC
Antiviral
25 µg/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

DRAVP 2.0

Other

ml), S. epidermidis ATCC 12228 (MIC 50 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. ag
Evidence 29 Activity

Activity

MIC
Antiviral
25 µg/mL

Target

L. monocytogenes ATCC 19112

Source & Reference

DRAVP 2.0

Other

0 ug/ml), S .pneumoniae ATCC 49619 (MIC 12.5 ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. agalactiae ATCC 12386 (MIC 50 ug/ml), P-aerugi
Evidence 30 Activity

Activity

MIC
Antiviral
50 µg/mL

Target

Enterococcus faecalis ATCC 29212

Source & Reference

DRAVP 2.0

Other

ug/ml), S. aureus ATCC 25923 (MIC 25 ug/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. agalactiae ATCC 12386 (MIC 50 ug/ml), P-aeruginosa ATCC 27853 (MIC>50 ug/ml), S-pyoge
Evidence 31 Activity

Activity

MIC
Antiviral
50 µg/mL

Target

Streptococcus agalactiae ATCC 12386

Source & Reference

DRAVP 2.0

Other

g/ml), L. monocytogenes ATCC 19112 (MIC 25 ug/ml), E. faecalis ATCC 29212 (MIC 50 ug/ml), S. agalactiae ATCC 12386 (MIC 50 ug/ml), P-aeruginosa ATCC 27853 (MIC>50 ug/ml), S-pyogenes ATCC 19615 (MIC>50 ug/ml), S. mitis A
Evidence 32 Activity

Activity

MIC
Antiviral
50 µg/mL

Target

S. mitis ATCC 6249

Source & Reference

DRAVP 2.0

Other

50 ug/ml), P-aeruginosa ATCC 27853 (MIC>50 ug/ml), S-pyogenes ATCC 19615 (MIC>50 ug/ml), S. mitis ATCC 6249 (MIC 50 ug/ml), abd S-salivarius ATCC 13419 (MIC > 50 ug/ml). It also inhibits Herpes simplex virus 1 (H
Evidence 33 Activity

Activity

Blood-Brain Barrier
0.00234 mL/(g x min)

Assay & Model

Capillary deplition in situ b p
Unidirectonal influx rate constant

Source & Reference

NA
B3Pdb

Other

human
Direct iodination
Evidence 34 Activity

Activity

Blood-Brain Barrier
7 (cpm brain/mg)/(cpm blood/µl)

Assay & Model

RadioactiInitial disrobution volumety ratio

Source & Reference

NA
B3Pdb

Other

human
Intravenous
Permeability
direct iodination
Additional Detail Fields 1 fields
Intravenous